BioSight Ltd.

31 articles with BioSight Ltd.

• Biosight Launches a Phase 1/2 Clinical Trial of Aspacytarabine in Combination with Venetoclax for First-Line AML Induction Therapy, Followed by Aspacytarabine Consolidation

  11/22/2022

  Biosight Ltd today announced enrollment of a first patient to a phase 1/2 clinical trial designed to evaluate the safety and efficacy of its lead asset aspacytarabine (BST-236) in combination with the BCL2 inhibitor venetoclax for induction therapy of newly-diagnosed Acute Myeloid Leukemia (AML), followed by aspacytarabine single-agent consolidation therapy.

• Biosight Granted Orphan Drug Designation from the FDA for Aspacytarabine for the Treatment of Myelodysplastic Syndromes

  8/1/2022

  Biosight Ltd., announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to aspacytarabine (BST-236), an investigational novel antimetabolite, for the treatment of myelodysplastic syndromes, in addition to the Orphan Drug Designation granted in 2019 for aspacytarabine for the treatment of acute myeloid leukemia (AML).

• 

  Clinical Catch-Up: January 3-7

  1/10/2022

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.

• Biosight Reports Final Primary Endpoint Data from Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy

  1/6/2022

  Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced final results for the primary study endpoint, complete remission (CR), from the Company’s Phase 2b clinical trial evaluating single-agent aspacytarabine (BST-236) as a first-line acute myeloid leukemia (AML) therapy for patients unfit for standard induction chemotherapy.

• Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and Satisfy Initial Listing Requirements

  11/22/2021

  Advaxis, Inc. announced that it has received a letter from the Nasdaq Hearings Panel providing Advaxis an extension through December 20, 2021, to complete its business combination with Biosight, Ltd. and demonstrate compliance with all applicable requirements for initial listing on The Nasdaq Capital Market.

• Biosight Announces Initiation of Phase 2 Clinical Trial of Aspacytarabine for MDS and AML

  11/12/2021

  Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the initiation of a Phase 2 trial to evaluate aspacytarabine (BST-236), Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

• Biosight Announces Upcoming Presentation at the 63rd American Society of Hematology Annual Meeting

  11/4/2021

  Biosight Ltd., today announced that an abstract has been accepted for presentation at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting.

• 

  Clinical Catch-Up: August 16-20

  8/23/2021

  It was another busy week in clinical trial news. Here’s a look.

• Biosight Announces Initiation of Investigator Sponsored Phase 2 Clinical Trial of Aspacytarabine for Relapsed/Refractory AML and MDS with the Groupe Francophone des Myélodysplasies

  8/16/2021

  Biosight Ltd . today announced the initiation of a Phase 2 trial to evaluate aspacytarabine (BST-236), Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

• Advaxis and Biosight Announce Entry into Definitive Merger Agreement

  7/6/2021

  Advaxis, Inc. and Biosight Ltd., a privately held pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, announced that the companies have entered into a definitive merger agreement pursuant to which the shareholders of Biosight will become the majority holders of the combined company immediately following completion of the transaction.

• Biosight Presents Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) in an Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

  6/4/2021

  Biosight Ltd., today presents updated clinical data from the Company’s ongoing Phase 2b clinical trial evaluating single-agent aspacytarabine (BST-236

• Biosight Appoints Dr. Darrel Cohen as Chief Medical Officer

  5/18/2021

  Industry veteran brings successful track record of clinical development and marketing authorizations of several cancer and leukemia drug products Appointment establishes US presence of senior Biosight leadership

• Biosight Completes Enrollment in Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy

  5/11/2021

  Encouraging data support single-agent efficacy across key measures including complete remission (CR) with negative minimal residual disease (MRD) rates, duration of response and overall survival in front-line therapy of AML patients unfit for intensive chemotherapy

• Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2021 ASCO Annual Meeting

  4/28/2021

  Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced an abstract has been accepted for an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting which will be held virtually from June 4-8, 2021.

• Biosight Receives Orphan Medicinal Product Designation from the European Medicines Agency for Aspacytarabine (BST-236) for the Treatment of Acute Myeloid Leukemia

  12/17/2020

  Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation to aspacytarabine (BST-236) for the treatment of acute myeloid leukemia (AML)

• Biosight Presents Updated New Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting

  12/7/2020

  Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the presentation of updated clinical data from the Company’s ongoing Phase 2b trial evaluating aspacytarabine (BST-236) as a single-agent first-line acute myeloid leukemia (AML) therapy for patients unfit for standard chemotherapy at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

• Biosight Closes $46M Series C Financing to Advance Clinical Oncology ProgramsProceeds support expanded clinical program of BST-236, a proprietary anti-metabolite enabling high-dose chemotherapy with reduced systemic toxicity

  12/2/2020

  Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the deferred closing of its Series C financing, raising an additional $27M to the $19M announced earlier this year for total proceeds of $46M.

• Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual MeetingAbstract selected for virtual Poster Walk panel discussion with leading KOLs

  11/5/2020

  Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced an abstract has been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held virtually from December 5-8, 2020

• Biosight Granted U.S. FDA Fast Track Designation for BST-236 for the Treatment of Acute Myeloid Leukemia

  8/4/2020

  Biosight Ltd. announced that that the U.S. Food and Drug Administration has granted Fast Track designation for BST-236 for the treatment of acute myeloid leukemia in adults who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

• Biosight Announces Clinical Trial Collaboration with the European Cooperative Group, Groupe Francophone des MyélodysplasiesInitiation of Phase 2 Trial Evaluating BST-236 in Second Line Relapsed/Refractory MDS and AML Expected in Q4 2020

  7/21/2020

  Biosight Ltd ., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced that it has entered into a clinical trial agreement with the French  Study Group of the European Myelodysplastic Syndromes (MDS) Cooperative Group (EMSCO) led by Dr. Pierre Fenaux, the Groupe Francophone des Myélodysplasies (GFM). GFM is a non-profit organization comprised of most French he